Cargando…

Pharmacometabolomic Signature of Ataxia SCA1 Mouse Model and Lithium Effects

We have shown that lithium treatment improves motor coordination in a spinocerebellar ataxia type 1 (SCA1) disease mouse model (Sca1(154Q/+)). To learn more about disease pathogenesis and molecular contributions to the neuroprotective effects of lithium, we investigated metabolomic profiles of cereb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perroud, Bertrand, Jafar-Nejad, Paymaan, Wikoff, William R., Gatchel, Jennifer R., Wang, Lu, Barupal, Dinesh K., Crespo-Barreto, Juan, Fiehn, Oliver, Zoghbi, Huda Y., Kaddurah-Daouk, Rima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732229/ https://www.ncbi.nlm.nih.gov/pubmed/23936457 http://dx.doi.org/10.1371/journal.pone.0070610

Ejemplares similares

Pharmacometabolomics Reveals Racial Differences in Response to Atenolol Treatment
por: Wikoff, William R., et al.
Publicado: (2013)

Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine
por: Beger, Richard D., et al.
Publicado: (2020)

Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo
por: Kaddurah-Daouk, R, et al.
Publicado: (2013)

Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans
por: Rotroff, Daniel M., et al.
Publicado: (2016)

Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed-Pharmacogenomics
por: Yerges-Armstrong, Laura M., et al.
Publicado: (2013)

Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder – Possible Role for Methoxyindole Pathway
por: Zhu, Hongjie, et al.
Publicado: (2013)

Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate
por: Kaddurah‐Daouk, Rima, et al.
Publicado: (2018)

Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes
por: Rotroff, DM, et al.
Publicado: (2015)

A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2015)

Oxylipid Profile of Low‐Dose Aspirin Exposure: A Pharmacometabolomics Study
por: Ellero‐Simatos, Sandrine, et al.
Publicado: (2015)

Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology
por: Barupal, Dinesh Kumar, et al.
Publicado: (2019)

Lithium Therapy Improves Neurological Function and Hippocampal Dendritic Arborization in a Spinocerebellar Ataxia Type 1 Mouse Model
por: Watase, Kei, et al.
Publicado: (2007)

Pharmacometabolomics Reveals That Serotonin Is Implicated in Aspirin Response Variability
por: Ellero-Simatos, S, et al.
Publicado: (2014)

Generation and quality control of lipidomics data for the alzheimer’s disease neuroimaging initiative cohort
por: Barupal, Dinesh Kumar, et al.
Publicado: (2018)

Metabolomics Reveals Amino Acids Contribute to Variation in Response to Simvastatin Treatment
por: Trupp, Miles, et al.
Publicado: (2012)

Partial loss of Tip60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model
por: Gehrking, Kristin M., et al.
Publicado: (2011)

Prioritization of metabolic genes as novel therapeutic targets in estrogen-receptor negative breast tumors using multi-omics data and text mining
por: Barupal, Dinesh Kumar, et al.
Publicado: (2019)

Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2015)

Analysis of SCA8, SCA10, SCA12, SCA17 and SCA19 in patients with unknown spinocerebellar ataxia: a Thai multicentre study
por: Choubtum, Lulin, et al.
Publicado: (2015)

Metabolic Profiling of Patients with Schizophrenia
por: Kaddurah-Daouk, Rima
Publicado: (2006)

SCA8 should not be tested in isolation for ataxia
por: Roda, Ricardo H., et al.
Publicado: (2017)

Spinocerebellar ataxia type 31 (SCA31)
por: Ishikawa, Kinya
Publicado: (2022)

Partial Loss of Ataxin-1 Function Contributes to Transcriptional Dysregulation in Spinocerebellar Ataxia Type 1 Pathogenesis
por: Crespo-Barreto, Juan, et al.
Publicado: (2010)

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
por: Gupta, M, et al.
Publicado: (2016)

Motor neuron degeneration correlates with respiratory dysfunction in SCA1
por: Orengo, James P., et al.
Publicado: (2018)

Clinical and neuroradiological features of spinocerebellar ataxia 38 (SCA38)
por: Borroni, Barbara, et al.
Publicado: (2016)

MME mutation in dominant spinocerebellar ataxia with neuropathy (SCA43)
por: Depondt, Chantal, et al.
Publicado: (2016)

Differential Temporal Dynamics of Axial and Appendicular Ataxia in SCA3
por: Maas, Roderick P.P.W.M., et al.
Publicado: (2022)

Chemical Similarity Enrichment Analysis (ChemRICH) as alternative to biochemical pathway mapping for metabolomic datasets
por: Barupal, Dinesh Kumar, et al.
Publicado: (2017)

Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach
por: Barupal, Dinesh Kumar, et al.
Publicado: (2019)

Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease
por: Katsila, Theodora, et al.
Publicado: (2016)

Pharmacometabolomics in Early‐Phase Clinical Development
por: Burt, T, et al.
Publicado: (2016)

Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication
por: Jian, Jingai, et al.
Publicado: (2023)

Molecular mechanisms underlying Spinocerebellar Ataxia 17 (SCA17) pathogenesis
por: Yang, Su, et al.
Publicado: (2016)

Disrupted Calcium Signaling in Animal Models of Human Spinocerebellar Ataxia (SCA)
por: Prestori, Francesca, et al.
Publicado: (2019)

IDSL.GOA: Gene Ontology Analysis for Metabolomics
por: Mahajan, Priyanka, et al.
Publicado: (2023)

Pharmacometabolomics Informs Viromics toward Precision Medicine
por: Balasopoulou, Angeliki, et al.
Publicado: (2016)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Pharmacometabolomics by NMR in Oncology: A Systematic Review
por: Gómez-Cebrián, Nuria, et al.
Publicado: (2021)

Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers
por: Amaro, Filipa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7b9s2ik30ol30qpf6jko909300